Full Text
PCN50 COST-MINIMIZATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXED AS A SECOND-LINE TRETAMENT OF ADVANCED NON-SMALL LUNG CANCER (NSCLC) IN THE CONDITIONS OF THE CZECH REPUBLIC

Abstract

Authors

E Suchankova T Doleal

Back to Volume 11, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×